Product Development and Launch - Sure Shot Inc. completed the asset purchase of the dietary supplement product Sure Shot for a total consideration of $200,000 and 5,000,000 common shares [138]. - The Sure Shot Dietary Supplement is formulated to reduce blood alcohol content and contains 28 active ingredients, all classified as Generally Recognized As Safe (GRAS) [127]. - The Company launched the Sure Shot Dietary Supplement in December 2023 through its website, Amazon, and several Big Box stores [126]. - The Company has conducted clinical trials showing a statistically significant reduction in Blood Alcohol Content (BAC) among participants using the Sure Shot Dietary Supplement [131]. - The asset purchase included five patents related to the Sure Shot Dietary Supplement, enhancing the Company's intellectual property portfolio [139]. Financial Performance - The company generated $110,213 in revenues for the three months ended September 30, 2024, compared to $11,877 in the same period of 2023, representing a significant increase [178]. - Total operating expenses for the three months ended September 30, 2024, were $11,348,320, compared to $4,090,608 for the same period in 2023, indicating a substantial rise in expenses [179]. - The net loss for the three months ended September 30, 2024, was $11,929,277, compared to a net loss of $7,738,301 for the same period in 2023, reflecting an increase in losses [177]. - For the nine months ended September 30, 2024, the company generated revenues of $519,793, a significant increase from $69,968 in the same period of 2023, attributed to the launch of the Safety Shot Dietary Supplement [185]. - Total operating expenses for the nine months ended September 30, 2024, were $32,923,489, compared to $7,040,858 for the same period in 2023, indicating a substantial increase in operational costs [186]. - The company reported a net loss of $35,878,042 for the nine months ended September 30, 2024, compared to a net loss of $9,406,066 for the same period in 2023 [193]. Research and Development - The Company is committed to continuous improvement through innovation, with significant investments in research and development [135]. - Research and development expenses for the nine months ended September 30, 2024, were $271,719, compared to $98,091 for the same period in 2023, showing a significant increase in investment in R&D [169]. Operational Challenges - Sales during Q3 were down as the Company transitioned from a 12oz product to a 4oz product and powder packs, addressing consumer feedback on packaging and taste [133]. - The company incurred a net loss from operations of $(11,630,093) for the three months ended September 30, 2024, compared to $(7,277,606) for the same period in 2023, highlighting operational challenges [177]. - The gross profit (loss) for the nine months ended September 30, 2024, was $(2,029,306), compared to $(28,009) in 2023, reflecting challenges in cost management [184]. Marketing and Expenses - Marketing expenses for the nine months ended September 30, 2024, were $6,230,903, significantly higher than $206,047 in the same period of 2023, reflecting an aggressive marketing strategy [187]. - Legal and professional expenses for the nine months ended September 30, 2024, totaled $6,839,639, compared to $2,563,047 in 2023, indicating increased costs associated with corporate advisory services and governance [187]. - Stock-based compensation for the nine months ended September 30, 2024, was $16,411,690, a notable rise from $1,465,029 in the same period of 2023 [187]. Liquidity and Financial Position - The company had no cash equivalents as of September 30, 2024, or December 31, 2023, indicating a potential liquidity concern [155]. - The weighted average number of common shares outstanding during the three months ended September 30, 2024, was 55,930,639, compared to 29,836,485 for the same period in 2023, reflecting an increase in shares [157]. - Basic loss per share for the three months ended September 30, 2024, was $(0.21), compared to $(0.26) for the same period in 2023, indicating a slight improvement in loss per share despite increased losses [157]. - The company has not recognized an allowance for doubtful collections as of September 30, 2024, indicating confidence in receivables management [161]. Discontinued Operations - The company signed a separation agreement with Caring Brands, Inc., which is no longer a subsidiary, and all operations under this product line are now considered discontinued [181]. - The company incurred a loss from discontinued operations of $299,184 for the nine months ended September 30, 2024, compared to a loss of $261,528 in 2023 [191]. - Other income for the nine months ended September 30, 2024, included a recognized gain on the sale of stock of $231,159, while interest expense was $252,108 [189].
JUPITER WELLNESS(JUPW) - 2024 Q3 - Quarterly Report